HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. - Wikidata - wikimedia - TriplyDB

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

http://www.wikidata.org/entity/Q39252741

about

Oncogenes strike a balance between cellular growth and homeostasis Role of amino acid transporters in amino acid sensing The catalytic subunit of the system L1 amino acid transporter (slc7a5) facilitates nutrient signalling in mouse skeletal muscle VHL, the story of a tumour suppressor gene.The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters.L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.Histological Characterization of the Tumorigenic "Peri-Necrotic Niche" Harboring Quiescent Stem-Like Tumor Cells in Glioblastoma Amino Acid Transport Associated to Cluster of Differentiation 98 Heavy Chain (CD98hc) Is at the Cross-road of Oxidative Stress and Amino Acid Availability.Meeting report from the 2nd International Symposium on New Frontiers in Cardiovascular Research. Protecting the cardiovascular system from ischemia: between bench and bedside Nutrient transporters: the Achilles' heel of anabolism.Complex role of HIF in cancer: the known, the unknown, and the unexpected.SLC7A5 Functions as a Downstream Target Modulated by CRKL in Metastasis Process of Gastric Cancer SGC-7901 Cells.Cell cycle progression in response to oxygen levels.Glutaminolysis as a target for cancer therapy.Glutamine transporters in mammalian cells and their functions in physiology and cancer.Hypoxia and cellular metabolism in tumour pathophysiology.Dexamethasone Downregulates SLC7A5 Expression and Promotes Cell Cycle Arrest, Autophagy and Apoptosis in BeWo Cells.Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.Oxygen availability and metabolic adaptations.Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment.Harnessing Solute Carrier Transporters for Precision Oncology.Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.HIF-2α-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction Role Of Hif2α Oxygen Sensing Pathway In Bronchial Epithelial Club Cell Proliferation Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.Bioinformatics and Gene Network Analyses of the Swine Mammary Gland Transcriptome during Late Gestation.Impaired liver regeneration after hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy.Hypoxia favors myosin heavy chain beta gene expression in an Hif-1alpha-dependent manner.Mediator MED18 subunit plays a negative role in transcription via the CDK/cyclin module.Role of SLC7A5 in Metabolic Reprogramming of Human Monocyte/Macrophage Immune Responses.The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.HIF-2α is essential for carotid body development and function.Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health.Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins

P2860

Q26798085-52FD22C3-B2FE-4B36-A3CA-DAA81C094DB6 Q26999339-93643999-2DDE-4AF6-8625-91918FC5723D Q27320544-0A8EEBE6-31E1-488D-9001-3551108B767B Q34455226-4D7664EC-D3B4-4F9A-8DD8-FF23EF15863F Q35478977-11B31661-3640-4C1A-898C-5BE09DA5D067 Q35655815-891D05F0-13AC-4591-97A2-8906F872635B Q35757977-B0B02CA5-F355-41FB-A58D-7173FE9C54D3 Q35901357-0975B578-108A-4F93-9ACC-63FAB7914E48 Q35946641-F3E55087-6D07-4AFC-B022-05D5B86BED9D Q36371672-EAB675FF-C080-49EB-8839-E1CA2B640938 Q36741646-9A52DE31-8E51-4F2C-A25B-18943A4B4312 Q37301016-572ACB21-BFF5-480C-925E-5DB8545A4DBD Q37419580-56C5E4B2-6E8F-4F3A-9C70-6BEF937B784B Q38214442-40486B07-8E22-4531-AFAA-71DE276CBF29 Q38642387-FB007A82-D510-4C1F-BE81-0257B166C54F Q38685207-57433CB5-5449-43FC-BC42-9CE799EA7961 Q38772023-AD0191D0-222D-4126-9EC3-83B7C760D0E8 Q38861780-BB59777B-2988-4C47-9B03-C70ECA68AE3D Q38881946-FDE5ADE5-D543-4511-A2F7-B456790DEC69 Q38892263-55BABD8C-6547-4BDB-8E54-EB6E7768B002 Q38930757-B47451E8-ABF1-40CE-BD93-F5A5298EBE78 Q38957845-3A4713F8-0AB2-460F-8D8F-329BF7EDF8F3 Q38961810-CBA6DE56-B590-46D0-9380-A0EF7BE8163C Q39112756-8E5FB65C-D5E0-4423-A232-F53E50179771 Q39204754-2009356D-8949-4E44-9DC6-259D71E48DFD Q39284030-C6001300-6C98-46CC-982F-7757C1EA4087 Q40390084-AD4FDFB6-2A78-4AE9-A141-A881CA69017F Q41085568-278501E4-3F80-456F-8D54-EBF1B6C42CBB Q41966602-AAA7D636-0097-420E-9093-C20E1DAECFFE Q43067642-BB8F3998-0BEF-4179-8080-0F3C1D8D075B Q45870584-18B32B64-1451-4A2E-959E-AB7435704544 Q47096841-5B1CFE53-F3D2-44F0-BC3C-4705EE3FDFB4 Q48863240-0F954AA7-2A30-4F60-A9F9-DC3CDBCAEE67 Q49365787-F1885F7F-4697-4777-AB91-981FE0C85C85 Q50078157-FDAAAD07-30CB-4994-A6AD-0CE76D131EA3 Q52724909-420EE738-F314-4420-B8AF-CBBCC59B1974 Q55338865-EEE3BD75-64CF-4977-9C5C-F3A8AEC824B8 Q55419613-56BCAB79-CE1B-46AE-8B5C-485BCBE92E1F Q55514831-C20C0372-83ED-4760-A68D-27C755BCDB4E Q58605684-DCC00030-3F00-4FD0-8F65-97C1B44BEAD8

P2860

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

http://www.wikidata.org/entity/Q39252741

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@en

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@nl

type

label

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@en

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@nl

prefLabel

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@en

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.

@nl

P1433

Q39252741-52C36C40-CABB-46FA-8034-EF2EF17120A0

P1476

Q39252741-D34F40BF-38D2-4638-9BB9-A6B6969FE3A8

P2093

Q39252741-043838C1-CCE1-4759-ADB3-7BEB1B2EAEB3

Q39252741-0F5084F8-53CB-420C-9DD7-003AE4634C64

Q39252741-1D2B9D09-4D2B-4180-A849-5043BC212F64

Q39252741-29573A0E-A235-4CAF-9361-0B55293EFF1B

Q39252741-35C927FF-272C-4AF3-8FC5-0D5457902392

Q39252741-61817B0C-F7E9-4A81-A067-89B76DCBCFC3

Q39252741-A75F31FB-A5A1-4417-8659-1B422BB3D468

Q39252741-B260F7A6-7DB2-47F6-B92D-D664D5D38919

Q39252741-B9717F7A-909C-4906-A83A-A9C43CFDC968

Q39252741-C732F51F-5704-490D-99D3-D2474D6759CB

P304

Q39252741-ABF845E3-F053-4DAE-88F9-4B32EC36B417

P31

Q39252741-A150C5ED-F67E-4032-AD20-D3D728388BCC

P356

Q39252741-B1B46CE5-2576-4343-A649-09D539714BB8

P433

Q39252741-B97CF834-E3B1-476B-A8C2-6C648BBEED7A

P478

Q39252741-74D81474-F649-46FA-BAC6-CB8159BD191C

P50

Q39252741-3029959C-46DE-4708-BE89-95554D3D5B26

Q39252741-3587EA2A-E0FD-4C06-9B2F-70EDEDE02FD7

Q39252741-5516EC2A-DC1D-4B35-8118-277E7203EFBE

Q39252741-553494F5-F23E-4EC0-A4B2-53BB915E2880

Q39252741-6E1D0BDB-BA00-43C3-A9E0-B272314433CD

Q39252741-8F1A9113-164B-4285-AB36-017850D92B92

Q39252741-A666DB73-05D4-4B2F-8230-BE3F2976C658

Q39252741-C7AEA7D4-402E-4494-878A-F8923275FEF3

P577

Q39252741-DCFCD341-DBA8-49E8-BE69-CA97463B09B1

P5875

Q39252741-4648DA1E-EC26-4E2D-92F5-5A95E00CE05C

P698

Q39252741-80C30268-5AAB-4C91-8195-2C946C24FAA9

P356

J.MOLCEL.2012.09.017

P1433

P1476

HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5

@en

P2093

Ainara Elorza

http://www.w3.org/2001/XMLSchema#string

Alicia Vara-Vega

http://www.w3.org/2001/XMLSchema#string

Angel Ordóñez

http://www.w3.org/2001/XMLSchema#string

Antonio Salinas

http://www.w3.org/2001/XMLSchema#string

Florinda Meléndez-Rodríguez

http://www.w3.org/2001/XMLSchema#string

Inés Soro-Arnáiz

http://www.w3.org/2001/XMLSchema#string

Leticia Serrano-Oviedo

http://www.w3.org/2001/XMLSchema#string

Lucas Albacete-Albacete

http://www.w3.org/2001/XMLSchema#string

Manuel O Landázuri

http://www.w3.org/2001/XMLSchema#string

Rafael Martín del Río

http://www.w3.org/2001/XMLSchema#string

P304

681-691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLCEL.2012.09.017

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

Marcos Malumbres

José M Gimenez-Bachs

Francisco Sánchez-Madrid

Guillermo de Cárcer

Ricardo Sanchez-Prieto

Barbara Acosta-Iborra

P577

2012-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232719759

http://www.w3.org/2001/XMLSchema#string

P698

23103253

http://www.w3.org/2001/XMLSchema#string